. Author manuscript; available in PMC: 2013 Jun 6.

Published in final edited form as: J Child Neurol. 2008 Oct;23(10):1195–1204. doi: 10.1177/0883073808321769

Table 1.

Recent Treatment Strategies for Infant Embryonal Tumors

	Treatment	5-y EFS (%)	(Ref)
MB	Chemotherapy (vcr/cis/cyclo/vp16 or carbo/ifos/vp16) and delayed RT	32 +/− 5	(54)
	Chemotherapy (vcr/cyclo/carbo/vp16/mtx) and IT mtx	82 +/− 9 (CR) 50 +/− 13 (PR) 33 +/− 14 (M+)	(41)
	Chemotherapy (no mtx) alone, then HDCT + RT if evidence of progression/relapse	29 (CR) 6 (PR) 13 (M+)	(57)
sPNET	Chemotherapy (vcr/cis/cyclo/vp16 or carbo/ifos/vp16) and delayed RT	17 +/− 6	(54)
	Chemotherapy (multi-agent) alone	14	(65)
	Chemotherapy (multi-agent) +/− HD-mtx followed by HDCT and autologous PBSC	39	(70)
ATRT	Chemotherapy (vcr/cis/cyclo/vp16 or carbo/ifos/vp16) and delayed RT	14 +/− 7	(54)

Abbreviations: carbo = carboplatin; CR = complete resection; cyclo = cyclophosphamide; EFS = event-free survival; ifos = ifosfamide; HDCT = high-dose chemotherapy; HD-mtx = high-dose methotrexate; IT = intrathecal; M+ = metastatic disease at diagnosis; mtx = methotrexate; PBSC = peripheral blood stem cell rescue; PR = partial resection; Ref = reference citation; RT = radiotherapy; vcr = vincristine; vp16 = etoposide.